| Literature DB >> 30935025 |
Jacinthe Frangieh1, Yahya Salma2,3, Katia Haddad4, Cesar Mattei5, Christian Legros6, Ziad Fajloun7,8, Dany El Obeid9.
Abstract
Bee venom is a mixture of several components with proven therapeutic benefits, among which are anti-inflammatory, analgesic, and various cardiovascular conditions. In this work, we analyzed for the first time the proteomic content and biological properties of the crude venom from Apis mellifera syriaca, a honeybee from the Middle East region. Using high-performance liquid chromatography-tandem mass spectrometry, we evidence the venom contains phospholipase A2, hyaluronidase, mast cell-degranulating peptide, adolapin, apamin, and melittin. The latter was purified by solid phase extraction method (SPE) and tested in parallel with crude venom for biological activities. Precisely, crude venom-but not melittin-exhibited antibacterial activity against Staphylococcus aureus and Pseudomonas aeruginosa strains. Alongside, hemolytic activity was observed in human blood subjected to the venom at high doses. A. mellifera syriaca venom displayed antioxidant activities, and not surprisingly, PLA2 catalytic activity. Eventually, the venom proved to exert antiproliferative effects against MCF-7 and 3T3 cancer cells lines. This first report of a new bee venom opens new avenues for therapeutic uses of bee venoms.Entities:
Keywords: Apis mellifera syriaca; LC-ESI-MS; bee venom; in vitro effects; melittin; solid phase extraction
Mesh:
Substances:
Year: 2019 PMID: 30935025 PMCID: PMC6521255 DOI: 10.3390/toxins11040191
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1A. mellifera syriaca (copyright Dani El Obeid).
Figure 2Fractionation of A. mellifera syriaca venom using LC-ESI-MS. (A) HPLC chromatogram showing reverse-phase C18 fractionation of the venom. (B) MS profile of the venom. (C) MS profile showing the peaks containing melittin and PLA2.
Figure 3Isolation of melittin from the venom of A. mellifera syriaca. (A) HPLC profile of the melittin-containing fraction as a function of time and increasing % of acetonitrile solvent. (B) MS profile of the same fraction.
Figure 4Antibacterial activity of A. mellifera syriaca venom. Growth inhibition of different bacterial strains by the venom as a percentage of the total inhibition by specific antibiotics (used as positive controls) is shown. H2O was used as a negative control. Crude venom inhibits bacterial growth of S. aureus and P. aeruginosa. Data are expressed as mean ± SD.
Figure 5Hemolytic activity of A. mellifera syriaca venom. Different concentrations of venom (2.5–50 µg/mL) were used and hemolysis was quantified as a % of the maximal activity induced by H2O. A dose-response effect was observed and a plateau was reached from 20 µg/mL.
Figure 6Antioxidant activity of A. mellifera syriaca venom. Different concentrations of venom (2.5–500 µg/mL) or melittin (100 µg/mL) were used, and absorbance was measured at 517 nm. Vitamin C was used as a positive control. The venom exhibits robust dose-dependent activity. Data are expressed as mean ± SD.
Figure 7Effect of A. mellifera syriaca venom on fatty acid release. Phosphatidylcholine (PC) was subjected to increasing concentrations of the venom (0.625–5 µg/mL). Fatty acid release was measured as described in the methods. The venom exerts PLA2 activity.
Figure 8Cytotoxicity effect of A. mellifera syriaca venom on two different cancer cell lines. (A) Cytotoxicity activity of the venom on MCF-7 cells. (B) Cytotoxicity activity of the venom on 3T3 cells. Data are expressed as mean ± SD (n = 3–4). Unpaired t-test: ns (no significant), * p < 0.05; *** p < 0.001 when compared with the control. At 10 μg/mL, the crude venom showed a cytotoxic activity which is more significant against MCF-7 cancers cells.